AskBorsa
ARSign up free
EGX·Health Care & Pharmaceuticals

Cairo Pharmaceuticals

CPCI
Fiscal year starts in July · currency EGP · latest: Annual 2026
Next results: Q1 2027 — expected around 17 December 2026published last year on 17 December 2025Results calendar ←
594.00EGP+0.67% today1w −0.7%1m −1.8%delayed · 3 November
Net profit · 2025
444million
▲ 80.3% vs 2024
Total assets · 2025
2.03billion
▲ 33.8% vs 2024
Shareholders' equity · 2025
1.05billion
▲ 25.7% vs 2024
Operating cash flow · 2025
379million
▲ 44.1% vs 2024

Key facts

Source: annual statements 2025
  • Cairo Pharmaceuticals's net profit in 2025 was 444 million EGP, up 80.3% from 246 million EGP in 2024.
  • Total assets at the end of 2025 were 2.03 billion EGP, and shareholders' equity 1.05 billion EGP.
  • Operating cash flow in 2025 was positive at 379 million EGP.

Cairo Pharmaceuticals's Q1 2027 results are expected around 17 December — we email you the day they land

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

AI summary

Preparing a summary of the latest results…

Ask about Cairo Pharmaceuticals
How much did Cairo Pharmaceuticals's net profit grow last year?What were total assets and shareholders' equity in the latest annual balance sheet?Was operating cash flow positive in the last three years?Type your question…Ask
3 free questions a day after signing up. With Google, no password.
Annual net profit last 5 years
Net profit
124million
166million
41.04million
246million
444million
20212022202320242025

Summarised financial statements

Excel · Pro
Swipe the table to see the other years.
Item · EGP20212022202320242025
Income statement
Net profit124 million166 million41.04 million246 million444 million
Gross profit268 million62.16 million242 million533 million823 million
Total assets1.07 billion1.17 billion1.26 billion1.52 billion2.03 billion
Total liabilities365 million375 million575 million683 million980 million
Shareholders' equity704 million794 million686 million832 million1.05 billion
Total liabilities and equity1.07 billion1.17 billion1.26 billion1.52 billion2.03 billion
Operating cash flow162 million51.83 million88.53 million263 million379 million
Investing cash flow-35.13 million3.49 million-12.51 million-232 million-118 million
Financing cash flow-19.43 million-75.2 million15.13 million-2.41 million-257 million
Net change in cash49.39 million-19.89 million27.51 million28.9 million2.93 million
Sign up free to see the full five years for every period.
Sign up free in seconds
With Google or your email, no password.

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. What does this line mean?

Results by period

One page per period: the figures against the same period a year earlier, and the official report.

Q3 2026Q2 2026Fiscal year 2025Q3 2025Q2 2025Q1 2025Fiscal year 2024Q4 2024Q3 2024Q1 2024Fiscal year 2023Q4 2023Q3 2023Q1 2023Fiscal year 2022Q4 2022Q3 2022Q2 2022Q1 2022Fiscal year 2021

Financial reports (17)

2026Annual
PDF
2026Q3
PDF
2026Q1
PDF
2026Q2
PDF
2025Q2
PDF
2025Annual
PDF
2025Q1
PDF
2025Q3
PDF
2024Q3
PDF
2024Q1
PDF
2023Q1
PDF
2023Annual
PDF
2022Annual
PDF
2022Q1
PDF
2022Q2
PDF
2022Q3
PDF
2021Annual
PDF

Other companies in Health Care & Pharmaceuticals

Ranked by latest annual net profit
All companies in the sector ←
EIPICOPHAR·1.1billion+33%Ibnsina PharmaISPH·952million+55%Cleopatra Hospitals GroupCLHO·824million+14%Alexandria PharmaceuticalsAXPH·660million+1132%Memphis PharmaceuticalsMPCI·480million−5%RamedaRMDA·387million+58%